T2 Biosystems, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 16 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-09-10: Reporting owner Barclay Alec; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-09-10: Reporting owner Sprague John M; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-09-10: Reporting owner Gibbs Michael Terrence; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-09-10: Reporting owner Lowery Thomas J.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-09-10 | Barclay Alec Officer (SVP, Operations) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $1.43 exercise price | 2019-09-13 | |
| 2019-09-10 | Sprague John M Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $1.43 exercise price | 2019-09-12 | |
| 2019-09-10 | Gibbs Michael Terrence Officer (General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $1.43 exercise price | 2019-09-12 | |
| 2019-09-10 | Lowery Thomas J. Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $1.43 exercise price | 2019-09-12 | |
| 2019-06-07 | Jones Adrian M Director | 4 | Stock Option (Right to Buy) Derivative · Indirect · See Footnotes | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,000 22,000 owned after | $1.54 exercise price | 2019-06-12 | |
| 2019-06-07 | Lapidus Stanley Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,000 22,000 owned after | $1.54 exercise price | 2019-06-11 | |
| 2019-06-07 | Elsbree David B Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,000 22,000 owned after | $1.54 exercise price | 2019-06-11 | |
| 2019-06-07 | CUMMING JOHN W Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,000 22,000 owned after | $1.54 exercise price | 2019-06-11 | |
| 2019-06-07 | LIEBMAN SEYMOUR Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,000 22,000 owned after | $1.54 exercise price | 2019-06-11 | |
| 2019-06-07 | Cima Michael J. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,000 22,000 owned after | $1.54 exercise price | 2019-06-11 | |
| 2019-02-21 | Gibbs Michael Terrence Officer (General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $3.72 exercise price | 2019-02-25 | |
| 2019-02-21 | McDonough John Director, Officer (President & CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $3.72 exercise price | 2019-02-25 | |
| 2019-02-21 | Sprague John M Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $3.72 exercise price | 2019-02-25 | |
| 2019-02-21 | Barclay Alec Officer (SVP, Operations) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $3.72 exercise price | 2019-02-25 | |
| 2019-02-21 | Lowery Thomas J. Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $3.72 exercise price | 2019-02-25 | |
| 2019-01-03 holding as of filing | Jones Adrian M Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Indirect · See footnotes | Holding | 66,176 owned after | $8.92 exercise price | 2019-01-03 |